Spontaneous bacterial peritonitis
- Donald J. Hillebrand MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Spontaneous bacterial peritonitis (SBP) is the prototypical ascitic fluid infection occurring in patients with advanced liver disease and ascites. The key to successful treatment of SBP is a knowledge of appropriate antibiotic regimens and an understanding of the setting in which infection develops, particularly those individuals at high risk for infection. A high index of suspicion should lead to early diagnostic paracentesis and ascitic fluid analysis. Treatment of SBP involves the use of nonnephrotoxic broad-spectrum antibiotics expected to cover the typical bacterial flora associated with SBP. SBP typically involves infection with a single organism, with Escherichia coli, Klebsiella spp, and Streptococcus spp responsible for nearly three fourths of cases. The treatment of choice is cefotaxime 2 g given intravenously every 8 hours for a total of 5 days. The antibiotic regimen is adjusted based on the results of ascitic fluid cultures. Other antibiotic regimens for SBP are less well studied. Given the significant morbidity and mortality rates associated with SBP, efforts to prevent its development and recurrence with antibiotic prophylaxis are warranted. The most extensively studied form of prophylaxis involves selective intestinal decontamination (SID) with the oral fluoroquinolone norfloxacin. Individuals with low-protein ascites (ascitic fluid total protein < 1g/dL) benefit from SID with norfloxacin 400 mg daily during times of hospitalization. Long-term primary prophylaxis during outpatient management of individuals awaiting liver transplantation with severe ascites and advanced liver failure should also be considered. Patients with cirrhosis and upper gastrointestinal bleeding should receive norfloxacin 400 mg twice daily for 1 week following their bleed. Those individuals surviving an episode of SBP should be treated with norfloxacin 400 mg daily until the risk of SBP is removed by definitive resolution of the ascites or liver transplantation surgery. Although the infection-related mortality associated with SBP has decreased to less than 10%, hospitalization-related mortality remains as high as 30% as a result of the severe underlying liver disease in which the infection arises and the marked generation of cytokines and nitric oxide resulting from the infection. Recently, the simultaneous administration of intravenous albumin and antibiotics for SBP has been shown to result in the decreased development of azotemia and hospitalization-related mortality. Further improvement in the outcomes of SBP will require treatments targeting this cytokine cascade rather than the development of more potent antibiotics.
- Garcia-Tsao G: Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726–748. A comprehensive and well-organized consensus statement regarding management of the complications of cirrhosis including spontaneous bacterial peritonitis. CrossRef
- Bauer TM, Steinbruckner B, Brinkmann FE, et al.: Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001, 96:2962–2967. CrossRef
- Llovet JM, Bartoli R, March F, et al.: Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998, 28:307–313. CrossRef
- Chu CM, Chang KY, Liaw YF: Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995, 40:561–565. CrossRef
- Rimola A, Garcia-Tsao G, Navasa M, et al.: Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000, 32:142–153. A comprehensive evidence-based and expert opinion (International Ascites Club) formulated consensus regarding spontaneous bacterial peritonitis. CrossRef
- Rodriguez-Ramos C, Galan F, Diaz F, et al.: Expression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 2001, 46:1668–1676. CrossRef
- Navasa M, Follo A, Filella X, et al.: Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998, 27:1227–1232. CrossRef
- Bories PN, Campillo B, Azaou L, et al.: Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997, 25:1328–1333. CrossRef
- Hillebrand DJ, Runyon BA: Spontaneous bacterial peritonitis: keys to management. Hosp Pract 2000, 35:87–90, 96–8. CrossRef
- Gines P, Navasa M: Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? J Hepatol 1998, 29:490–494. A critical editorial of the published studies regarding antibiotic prophylaxis for SBP and recommendations regarding judicious use of prophylaxis. CrossRef
- Thuluvath PJ, Morss S, Thompson R: Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001, 96:1232–1236.
- Gross P, Wehrle R, Bussemaker E: Hyponatremia: pathophysiology, differential diagnosis and new aspects of treatment. Clin Nephrol 1996, 46:273–276.
- Soulsby CT, Morgan MY: Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom. BMJ 1999, 318:1391.
- Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med 1997, 337:473–479. CrossRef
- Franca AV, De Souza JB, Silva CM, et al.: Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with ceftriaxone. J Clin Gastroenterol 2001, 33:295–298. CrossRef
- Ricart E, Soriano G, Novella MT, et al.: Amoxicillinclavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000, 32:596–602. CrossRef
- Bernard B, Grange JD, Khac EN, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655–1661. A meta-analysis of published studies investigating the use of antibiotic prophylaxis in cirrhotic patients with gastrointestinal bleeding confirming benefit including survival advantage. CrossRef
- Navasa M, Follo A, Llovet JM, et al.: Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011–1017. CrossRef
- Hampel H, Bynum GD, Zamora E, et al.: Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. J Gastroenterol 2001, 96:2206–2210. CrossRef
- Terg R, Cobas S, Fassio E, et al.: Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000, 33:564–569. CrossRef
- Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403–409. A landmark, well-performed randomized clinical trial demonstrating a protective effect of intravenous albumin administration in SBP with decreased development of renal dysfunction and improved overall survival. CrossRef
- Lin OS, Wu SS, Chen YY, et al.: Bacterial peritonitis after elective endoscopic variceal ligation: a prospective study. Am J Gastroenterol 2000, 95:214–217. CrossRef
- Castells A, Salo J, Planas R, et al.: Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994, 20:584–591. CrossRef
- Guardiola J, Xiol X, Escriba JM, et al.: Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt. Am J Gastroenterol 1995, 90:2097–2102.
- Van Thiel DH, Hassanein T, Gurakar A, et al.: Liver transplantation after an acute episode of spontaneous bacterial peritonitis. Hepatogastroenterology 1996, 43:1584–1588.
- Jain A, Reyes J, Kashyap R, et al.: Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000, 232:490–500. Largest and longest retrospective study to date detailing long-term survival following liver transplantation from the University of Pittsburgh, which details 18 years’ median survival in adults. CrossRef
- Gines P, Tito L, Arroyo V, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493–1502.
- Rossle M, Ochs A, Gulberg V, et al.: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000, 342:1701–1707. An important randomized clinical trial of paracentesis and TIPS for refractory ascites confirming the clinical benefit of TIPS in selected patients with refractory ascites yet preserved liver synthetic function. CrossRef
- Malinchoc M, Kamath PS, Gordon FD, et al.: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31:864–871. CrossRef
- Grange JD, Roulot D, Pelletier G, et al.: Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998, 29:430–436. CrossRef
- Deschenes M, Villeneuve JP: Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999, 94:2193–2197.
- Terg R, Llano K, Cobas SM, et al.: Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol 1998, 29:437–442. CrossRef
- Fernandez J, Navasa M, Gomez J, et al.: Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140–148. CrossRef
- Ortiz J, Vila MC, Soriano G, et al.: Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999, 29:1064–1069. CrossRef
- Guarner C, Sola R, Soriano G, et al.: Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999, 117:414–419. An important study detailing risk factors for SBP development in patients with cirrhosis and ascites that helps identify potential groups of patients that may benefit from long-term primary antibiotic prophylaxis. CrossRef
- Das A: A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Am J Gastroenterol 1998, 93:1895–1900. CrossRef
- Inadomi J, Sonnenberg A: Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997, 113:1289–1294. CrossRef
- Llovet JM, Rodriguez-Iglesias P, Moitinho E, et al.: Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997, 26:88–95. CrossRef
- Singh N, Gayowski T, Yu VL, et al.: Trimethoprimsulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995, 122:595–598.
- Angeli P, Volpin R, Gerunda G, et al.: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29:1690–1697. CrossRef
- Spontaneous bacterial peritonitis
Current Treatment Options in Gastroenterology
Volume 5, Issue 6 , pp 479-489
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Loma Linda University Medical Center, 11234 Anderson Street, Room 1432, 92354, Loma Linda, CA, USA